OHSU Knight Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OHSU Knight Cancer Institute sits in the top decile of US sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count).
OHSU Knight Cancer Institute: 211 sponsored US clinical trials, 35 recruiting.
OHSU Knight Cancer Institute sponsors 211 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 94 completed. 5 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 6 trials.
Top-decile sponsor footprint
OHSU Knight Cancer Institute ranks in the top decile of sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
94 of 149 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
211 total, page 4 of 5
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
NCT00722072
Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
NCT00710151
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
NCT00691652
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
NCT00662103
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
NCT00642746
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
NCT00627276
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
NCT00516542
Docetaxel in Treating Patients With Relapsed Prostate Cancer
NCT00482274
Molecular Markers in Thyroid Cancer
NCT00598364
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
NCT00459810
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
NCT00660543
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
NCT00335478
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
NCT00659126
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00425386
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
NCT00381862
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
NCT00324324
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
NCT00321698
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00331409
Optimizing Body Composition & Health After Breast Cancer
NCT00659906
Exercise for Physical Health in Men With Prostate Cancer
NCT00660686
Strength Training for Older Breast Cancer Survivors
NCT00591747
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
NCT00428077
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
NCT00303849
Tissue Sample Collection From Patients With Fanconi Anemia
NCT00899522
Imatinib Mesylate in Treating Patients With Myelofibrosis
NCT00245128
Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer
NCT00253643
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
NCT00253513
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT00245037
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
NCT00243009
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
NCT00900302
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
NCT00238433
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors
NCT00238173
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
NCT00182741
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
NCT00103038
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00227682
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
NCT00248547
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
NCT00253552
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
NCT00238355
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
NCT00416884
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00258440
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
NCT00074165
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00053248
Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer
NCT00244894
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT00238199
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
NCT00899795
Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
NCT00896740
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00022490
Pre-Prostatectomy Celecoxib or Placebo
NCT02840162
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
NCT00015847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 73 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the OHSU Knight Cancer Institute pipeline
35 recruiting of 211 indexed (17% open); 94 completed (45%).
Phase mix: 5 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OHSU Knight Cancer Institute: open-pipeline peers nationwide
Peers matched on 211 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
OHSU Knight Cancer Institute sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 211 trials (± recruiting share)
- MedImmune · 210 trials · 0% recruiting
- University of Louisville · 217 trials · 21% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- Massachusetts General Hospital · 17% recruiting · 2,032 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this OHSU Knight Cancer Institute page
211 registered trials is a research-attention snapshot, not an endorsement of OHSU Knight Cancer Institute or any single study.
- 35 of OHSU Knight Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition OHSU Knight Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OHSU Knight Cancer Institute pipeline card: 211 registered trials from official public datasets.Report a data error.